.svg){kind=small}
Sep-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
Avexia is stocked at 503 licensed dispensaries across Illinois, New Jersey, and 8 other states, 147 of them in Illinois, with the deepest coverage in Chicago, Springfield, Normal, Quincy, and Schaumburg. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
Avexia’s mix in September 2026 tilted toward Topical at 41.52% share, yet Topical sales fell 33.19% year over year and 20.86% month over month, while Capsules rose 6.82% YoY and 8.83% MoM to 28.94% share; Concentrates held 22.41% share with a 40.40% YoY decline but a 10.28% MoM lift, and Tincture & Sublingual contracted 49.43% YoY and 5.27% MoM to 7.14% share. Overall brand sales declined 29.05% YoY alongside a 10.53% YoY drop in average price to $26.77, even as the brand held a Topical rank of 1 in Illinois; the pattern implies a portfolio still anchored in a shrinking flagship category while pockets of growth in Capsules and a MoM rebound in Concentrates are insufficient to offset Topical and Tincture erosion.
The shifts imply Avexia is overexposed to Topical volatility despite leading the Illinois Topical ranking at position 1, with pricing pressure (−10.53% YoY) not generating enough volume to counter a 33.19% YoY Topical drop and a 49.43% YoY decline in Tincture & Sublingual. The simultaneous 8.83% MoM gain in Capsules and 10.28% MoM gain in Concentrates against a 20.86% MoM Topical decline suggest reallocating focus toward ingestibles and extracts to diversify away from a single-category dependence that is pulling total sales down 29.05% YoY.
Competitive Landscape
Avexia holds #1 in IL Topical in September 2026 with a 0-position YoY rank change from #1, and it also maintained #1 over the last three months while matching its peak at #1 in September 2026; by contrast, Doctor Solomon's stayed at #2 YoY while posting a -13.8% sales change, and Alluris Wellness advanced from #6 to #5 with +153.3% YoY sales, indicating that Avexia’s flat rank trajectory at the top signals defensibility but rising pressure from fast-climbing challengers.
Notable Products
CBG/THC 1:1 Ascend Tablets 40-Pack (100mg CBG, 100mg THC) posted the standout movement in September 2026 with a +54.8% MoM surge to rank 5, while CBD/THC 1:1 Harmony Micro-Dosed Tablets 40-Pack (100mg CBD,100mg THC) fell -23.8% to rank 4. The flagship CBD/THC 1:1 Harmony Pain Relief Balm (100mg CBD, 100mg THC, 2oz) retained rank 1 despite a -18.9% MoM decline, and the category skew shows concentration with four of the top ten in Capsules alongside three Topicals. This pattern implies Avexia is pivoting toward diversified cannabinoid tablet formats to offset softness in legacy Topicals, reallocating demand within the top five even as total Topicals volume cools.
CBD/THC 4:1 Relief Tablets 40-Pack (400mg CBD, 100mg THC) advanced +15.6% MoM at rank 2, contrasting with CBD/THC 1:1 Harmony Pain Relief Lotion (100mg CBD, 100mg THC, 2oz) dropping -28.5% at rank 6 and Lavender Epsom Bath Soak (100mg THC, 6oz) sliding -17.6% at rank 8. Concentrates were mixed, with Purple Lemon Punch RSO Syringe (0.5g) down -9.5% at rank 7 while Super Lemon G RSO Syringe (0.5g) entered the top ten at rank 9 with no prior MoM baseline; combined with Tincture & Sublingual at rank 10 slipping -3.1%, the mid-pack is fragmenting across niches. The spread of gains in higher-rank Capsules against multi-item declines in Topicals signals a near-term assortment strategy favoring functional tablets over topical relief, concentrating future growth bets in capsule innovation rather than topical breadth.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
